Document is current
Any future updates will be listed below
-
Authors
Chihara, Dai https://orcid.org/0000-0002-1153-2294
Miljkovic, Milos https://orcid.org/0000-0001-5848-6320
Iyer, Swaminathan P.
Vega, Francisco https://orcid.org/0000-0001-5956-452X
- License Information
-
More Information
Article History
Received: 21 September 2020
Revised: 19 January 2021
Accepted: 8 February 2021
First Online: 4 March 2021
Compliance with ethical standards
:
: SPI has research support from Rhizen, Seattle Genetics, Spectrum (Acrotech), Affimed, Trillium, CRISPR Therapeutics, Legend Biotech, Daiichi Sankyo, Amgen and Consultant for Daiichi Sankyo, Sanofi, Seattle Genetics and Legend Biotech and speaker for Target Oncology and Curio Science. FV has research support from CRISPR Therapeutics and from NCI (R01 CA222918).
